NCT06478381

L218CAR19 in Patients With Relapsed/Refractory B-cell Lymphoma

A Phase 1, Open-label, Dose Escalating Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of L218CAR19 in Patients With CD19 Positive Relapsed/Refractory B-cell Lymphomas

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 22 (estimated)
• Sponsor: Henan Cancer Hospital · Other Government
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

L218CAR19 is a kind of chimeric antigen receptor T-cell immunotherapy targeting CD19 on B cells. The goal of this study is to determine the safety, tolerability, pharmacokinetics, pharmacodynamics and clinical activity of L218CAR19 in patients with B-cell lymphomas who have received at least two lines of systemic treatment.

Conditions

• Relapsed/Refractory B-cell Lymphomas

Interventions

Type	Name	Description
DRUG	L218CAR19	L218CAR19 is intravenously administered at three dose levels.

Timeline

• Start date: 2024-06-01
• Primary completion: 2025-12-31
• Completion: 2026-06-30
• First posted: 2024-06-27
• Last updated: 2024-06-27

Locations

1 site across 1 country: China